Buying Mirus for $125M, Roche Expands Stable of RNAi Delivery Technologies

After acquiring Alnylam Pharmaceuticals’ German subsidiary, Roche began looking beyond its own labs for enabling technologies. The planned purchase of Mirus Bio marks the latest step in that ongoing process.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.